Citations

Clear

353 citation(s) found for "Kaufman, PA".

Dual-Energy X-Ray Absorptiometry–Derived Body Composition Asymmetry in Pain-Free Adults
Sen, Soumyadip, Nikanpour, Yalda , Toutounchi, Saman , Gharibi, Orod , Kaufman, Kenton, Pignolo, Robert, Rezaei, Asghar

Mayo Clinic

American Journal of Physical Medicine & Rehabilitation | November 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/phm.0000000000003203 | PMID 43000644 Get It

Objective: To characterize body composition asymmetry in asymptomatic adults and examine its associations with age, lumbar intervertebral disc degeneration (DD), and physical activity. Design: Dual-energy X-ray absorptiometry scans were performed, and lumbar DD grading, and physical activity levels were assessed in clinically asymptomatic adults in this cross-sectional study. Results: Fifty-one participants were included. Asymmetry in trunk fat and lean tissue mass was present in the overall cohort ( P <0.0001), and leg lean tissue mass also differed between sides ( P =0.0178), with right-sided predominance in older participants ( P =0.0094). Trunk lean AI (TLAI) was higher in older than younger participants (6.3±4.9 vs. 3.5±2.6; P =0.012), whereas the corresponding trunk fat AI (TFAI) difference was not statistically significant (8.0±5.9 vs. 5.0±3.6; P =0.085). Greater age was associated with TLAI ( P =0.008), while the trunk fat association was less robust in sensitivity analyses. Signed TFAI and TLAI shifted toward non-dominant-side predominance with greater age ( P <0.05). Lumbar DD and physical activity were not significantly associated with asymmetry. Conclusion: Body composition asymmetry was most evident in the trunk. Trunk lean asymmetry was greater at older ages, whereas the corresponding trunk fat association was weaker. Because functional outcomes were not assessed, the clinical significance of these findings requires further investigation.
Epidemiologic Study of Transfusion-Related Alpha-Gal Syndrome
Kaufman, Richard M., Hoen, Anne G., Khan, Jenna, Knudson, C. Michael, Romero, Andres E. Mindiola, Mo, Allison , Takanashi, Minoko , Collaborative, UPTICK Study Group; for the Biomedical Excellence for Safer Transfusion (BEST), Cardigan, Rebecca, Stanworth, Simon J., Commins, Scott P. , Scherer, Emily A., Davenport, Robertson D., Afraz, Sajjad, Andrews, Jennifer , Casey, John, Sullivan, Jensyn Cone , Cousins, Clara C. , Giorgi, Valeria De , Delaney, Meghan, DelBaugh, Regina M. , Gilstad, Colleen W. , Gofton, Alexander , Hill, Kate, Hogan, Keenan , Humbrecht, Catherine , Ikeda, Kazuhiko, Javanbakht, Ayda, Juskewitch, Justin E, Wojtowicz, Monique M. Menzies, Miller, Maureen J., Mills, Georgia, Nelson, Anna C. , Pauly, Marie C., Poisson, Jessica , Raval, Jay S., Samy, Nikitha, Sato, Tomohiko, Takeda, Yoshinori , Thibodeaux, Suzanne R. , Nunen, Sheryl van, Virk, Mrigender S., West-Mitchell, Kamille, Yamanouchi, Jun, Yoshihara, Satoshi, Zheng, X. Long, Ziman, Alyssa, Cone Sullivan, Jensyn , Kaufman, Richard Max , Hoen, Anne Gatewood , Knudson, Charles Michael , Metcalf, Ryan A. , Schäfer, Richard , Dunbar, Nancy M. , Cardigan, Rebecca A. , Stanworth, Simon J., Scherer, Emily A. , Cervinski, Mark A , Arai, Yasuyuki , Brugnara, Carlo , Allen, Elizabeth S. , Aurich, Konstanze , Casey, John , Cohn, Claudia S. , Crowe, Elizabeth P , Delaney, Meghan , Hendrickson, Jeanne E. , Hill, Kate, Ikeda, Kazuhiko , Jacquot, Cyril , Javanbakht, Ayda , Juskewitch, Justin E. , Lu, Wen , Wojtowicz, Monique Menzies , Miller, Maureen J. , Nelson, Anna , Pagano, Monica B. , Pauly, Marie-Christin , Saifee, Nabiha H , Sato, Tomohiko, Takeda, Yoshinori, Tiberghien, Pierre , Nunen, Sheryl van, Virk, Mrigender , Wood, Erica M , Yoshihara, Satoshi , Zheng, X. Long, Ziman, Alyssa

Mayo Clinic

JAMA Internal Medicine | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamainternmed.2026.3983 | PMID 42636004 Get It

Importance Recent case reports suggest that B antigen–containing blood products may be associated with anaphylactic transfusion reactions in recipients with preformed immunoglobulin E to galactose- α -1,3-galactose (alpha-gal). Objective To test the association of local alpha-gal syndrome (AGS) prevalence and allergic transfusion reaction (ATR) in patients with blood type O. Design, Setting, and Participants In this international, multicenter, retrospective cohort study at academic medical centers, sites were assigned to AGS high- or low-prevalence clusters based on the known geographic distribution of AGS. Data were collected on platelet or plasma transfusions and ATRs during 2020 to 2024. Consecutive patients receiving platelet or plasma transfusions were included. Exposures Patients with blood type O who received B or AB units and patients with blood type O who received O units (reference group) in AGS high- and low-prevalence clusters were compared. Main Outcomes and Measures Before data collection, the hypothesis was that if transfusion-related alpha-gal syndrome (TRAGS) is a true clinical entity, excess ATRs to group B or AB units would be detected in AGS high-prevalence regions exclusively. The main measure was the overall risk ratio (RR) for ATRs to B or AB plasma or platelets in AGS high- vs low-prevalence clusters. Results In total, 558 823 platelet and plasma transfusions at 40 sites in 5 countries were analyzed, of which ATRs occurred in 1744 transfusions (0.3%). In the US AGS high-prevalence cluster (9 sites), significantly more ATRs of any severity occurred among patients with blood type O who received B or AB units vs patients with blood type O who received O units (overall RR, 3.93; 95% CI, 2.96-5.21; P &amp;lt; .001). In contrast, in the primary analysis of the AGS low-prevalence cluster (15 sites), excess ATRs to B or AB units were not detected. In subgroup analyses among patients with blood type O receiving B units, the RR for moderate to severe ATRs was 9.14 (95% CI, 5.39-15.52; P &amp;lt; .001) in the AGS high-prevalence cluster vs 2.15 (95% CI, 1.34-3.47; P = .002) in the AGS low-prevalence cluster. Outside the US, a signal consistent with TRAGS was not detected. Conclusions and Relevance This cohort study provides provocative epidemiologic evidence that TRAGS may be a unique manifestation of AGS and a previously unrecognized risk associated with transfusion. In AGS high-prevalence regions, blood collectors and hospital transfusion services should consider approaches to preventing severe ATRs from B or AB plasma or platelet units.
Impact of Anterior Load Carriage on Dynamic Sagittal Spinal Alignment
Bhat, Sandesh G., Barman, Apurba, Kaufman, Kenton R , Barman, Apurba , Rezaei, Asghar , Bhat, Sandesh G. , Kaufman, Kenton R.

Mayo Clinic

American Journal of Physical Medicine & Rehabilitation | August 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/phm.0000000000003128 | PMID 42587358 Get It

Objectives: To examine the effects of anterior load carriage on dynamic sagittal spinal alignment during the gait cycle in younger (<65 y) and older (≥65 y) adults. Design: Cross-sectional study of 47 participants aged 20–80 years categorized as young and older adults. Participants walked at self-selected speeds with and without a 4.5 kg anterior chest load. Whole-body kinematics were recorded using a 19-camera infrared motion capture system. Outcome measures included lumbar lordosis (LL), thoracic kyphosis (TK), trunk inclination (TI), sagittal trunk shift (STS), and pelvic tilt (PT). Gait-cycle–dependent differences were analyzed using statistical parametric mapping. Results: The mean age was 41 years in young adults (n=28) and 70 years in older adults (n=19). Anterior load carriage increased LL during portions of the gait cycle and reduced TI throughout the entire gait cycle. Younger adults demonstrated greater LL and lower TI than older adults. A significant age-by-load interaction for TI was observed during portions of the gait cycle. Conclusions: Anterior load carriage alters spinal alignment by increasing LL and reducing TI during walking, with distinct age-related patterns. These results provide valuable reference data and a foundation for future studies on load management and ergonomic interventions across the adult lifespan.
Concurrent Validity and Between-System Agreement of a Commercial Wearable Inertial Sensor System for Gait and Postural Sway Assessment in Progressive Supranuclear Palsy
Novotny, Ryan , You, Sungmin , Hogen, Cecilia A., Whitwell, Jennifer L. , Josephs, Keith A. , Kaufman, Kenton R. , Ali, Farwa , Novotny, Ryan E , You, Victor S , Josephs, Keith A , Kaufman, Kenton R , Ali, Farwa

Mayo Clinic

Sensors | August 12, 2026 | Volume: 26 | Issue: 16 | Pages: 5105

10.3390/s26165105 | PMID 42655415 Get It

Wearable inertial measurement units (IMUs) offer an accessible alternative to optical motion capture (MoCap) gait analysis, but their performance in Progressive Supranuclear Palsy (PSP) requires validation. We assessed the concurrent validity of IMU-derived versus MoCap-derived gait metrics and static postural sway in 30 patients with PSP using Bland–Altman analysis, Intraclass Correlation Coefficients (ICC), and Spearman rank correlations. Finally, we assessed equivalence using the Two one-sided tests (TOST) procedure. Multivariable linear regression was used to determine whether clinical severity, as measured by the PSP Rating Scale (PSPRS), independently predicted absolute IMU measurement error while controlling for patient age and gait velocity. IMUs demonstrated excellent between-system agreement for parameters such as cadence (100.76 ± 11.42 vs. 100.52 ± 11.59) and cycle time (1.21 ± 0.15 vs. 1.22 ± 0.15; ICC > 0.98), despite a systematic underestimation of gait velocity (p < 0.05). Agreement significantly diminished for micro-phases (e.g., single/double support times) and spatial asymmetry. Interestingly, the TOST procedure revealed that only sagittal and transverse trunk kinematics were equivalent between systems, with all other measures failing to find equivalency. For static sway, the IMU demonstrated strong rank-order correspondence for tracking relative postural instability (ρ = 0.82, p < 0.05). Multivariable analysis revealed that higher PSPRS scores are independently associated with greater between-system discrepancies in support phases and pelvic and trunk kinematics (p < 0.05), irrespective of reduced gait speed. These findings highlight the need to develop disease-specific algorithms, rather than relying on normative commercial models, to establish reliable digital biomarkers for monitoring progressive motor decline.
Renal Function Decline After Vascularized Composite Allotransplantation
Ouellet, Gabriel , Sardu, Claudia , Kanitakis, Jean , Amer, Hatem, Azari, Kodi , Badet, Lionel , Brandacher, Gerald , Cendales, Linda, Özkan, Özlenen , Gaillard, Christophe , Gazarian, Aram, Kaufman, Christina , Landín, Luis , Lanzetta, Marco , Levin, L. Scott , Sassu, Paolo , Satbhai, Nilesh, Morélon, Emmanuel , Dogan, Ozlenen , Kaminska, Dorota , Lanzetta, Marco , Levin, Scott , Morales, Martin Iglesias , Sassu, Paolo , Talbot, Simon , Weissenbacher, Annemarie , Thaunat, Olivier , Morelon, Emmanuel , Petruzzo, Palmina , Amer, Hatem , Badet, L. , Cendales, Linda C. , Kamińska, Dorota , Lassus, Patrik , Iglesias, Martín , Weißenbacher, Annemarie , Thaunat, Olivier

Mayo Clinic

Transplantation Direct | July 6, 2026 | Volume: 12 | Issue: 8 | Pages: e1976

10.1097/txd.0000000000001976 | PMID 42416359 Get It

Background. Chronic kidney disease (CKD) is a common complication of nonrenal transplantation, influencing recipients’ morbidity and mortality. The incidence of CKD varies depending on the transplanted organ. Recipients of vascularized composite allotransplantation (VCA) need lifelong immunosuppression similar to that of solid organ transplantation. This study investigated renal function in VCA recipients. Methods. We studied 70 recipients from 17 centers (median follow-up: 8 y): 59 upper extremity, 10 face, and 1 penis transplant. Pretransplant and posttransplant clinical data and sera were collected to calculate the estimated glomerular filtration rate (eGFR) using the CKD Epidemiology collaboration 2021 formula. Results. Pretransplantation, the median eGFR was 105.36 mL/min (range, 71.39–155.39 mL/min). By 3 mo posttransplant, the eGFR had significantly decreased to 78.42 mL/min (range, 32.49–130.74 mL/min; P = 0.001) before stabilizing. Despite higher tacrolimus levels at 3 mo, no correlation with eGFR was found. During follow-up, 17.1% of patients experienced a ≥50% eGFR decline, 10.9% progressed to CKD, and 4.7% developed end-stage kidney disease. Some risk factors were identified, but their responsibility could not be established with certainty because of the low number of severe renal outcomes. Conclusions. Renal function declines in the majority of VCA recipients, but the function loss is lower compared with nonrenal solid organ transplantation recipients. Although no statistically significant correlation could be established between tacrolimus exposure and renal function decline, strategies aiming at minimizing calcineurin inhibitor exposure and avoiding other nephrotoxic causes are recommended to preserve long-term kidney function.
Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
Wechalekar, Ashutosh , Sanchorawala, Vaishali , Zepeda, Victor H. Jimenez-, Suzuki, Kenshi, Lentzsch, Suzanne , Huart, Antoine , Carpinteiro, Alexander , Swenson, Eugene , Khan, Zilehuma, Catini, Julia, Kulkarni, Hrishikesh, Meltzer, Brian, Lake, Stephen, Liedtke, Michaela , Investigators, for the CARES, Ting, Stephen Bek Ngie, Mollee, Peter Norman, Meuleman, Nathalie, Delforge, Michel, Zepeda, Victor Jimenez, Zhang, Shuyang, Du, Xin, Wang, Jianan, Qian, Honglan, Sun, Chunyan, Belhadj, Karim , Arnulf, Bertrand, Karlin, Lionel, Macro, Margaret, Colella, Jean-Marc Schiano De, Stoppa, Anne-Marie, Viallard, Jean-Francois, Fenk, Roland, Hansen, Timon, Girke, Vera, Nogai, Axel, Gatt, Moshe, Lavi, Noa, Magen, Hila , Palladini, Giovanni, Pane, Fabrizio, Buda, Gabriele , Ishida, Tadao, Iida, Shinsuke, Jamroziak, Krzysztof, Byun, Jamin, Koh, Youngil, Kim, Kihyun, Villamediana, Ramón Lecumberri, Lopez, Maria Teresa Cibeira, Martínez, Irene Romera, Duarte, Rafael , Castello, Isabel Angela Krsnik, Garcia, Maria Esther Gonzalez , Chacon, Eusebio Narciso Martin, Martínez, Javier Alberto Rojas , Valent, Jason , Rosenzweig, Michael A., Chung, Alfred, Wong, Sandy, Bumma, Naresh , Comenzo, Raymond, Gaballa, Mahmoud, Lee, Hans C., Kaufman, Gregory P., Passero, Frank, Stockerl-Goldstein, Keith, Waxman, Adam, D'Souza, Anita, Cowan, Andrew, Lee, Sarah, Libby, Edward, Godara, Amandeep , Kovacsovics, Tibor, Sengsayadeth, Salyka, Goodman, Stacey , Chaulagain, Chakra, Wechalekar, Ashutosh D. , Dispenzieri, Angela , Sanchorawala, Vaishali , Kastritis, Efstathios , Lentzsch, Suzanne , Meltzer, Brian , Liedtke, Michaela , Dispenzieri, Angela , Kastritis, Efstathios , Bhutani, Divaya , Bianchi, Giada , Suzuki, Kenshi , Khan, Zilehuma, Kulkarni, Hrishikesh, Lake, Stephen, Ting, Stephen B. , Mollee, Peter , Agis, Hermine , Straßl, Irene , Meuleman, Nathalie , Delforge, Michel , Sedlák, František , Jaccard, Arnaud , Arnulf, Bertrand , Karlin, Lionel , Macro, Margaret , Stoppa, Anne‐Marie, Bridoux, Frank , Chalopin, Thomas , Viallard, Jean‐François , Fenk, Roland , Symeonidis, Argiris , Annibali, Ombretta , Iida, Shinsuke, Ikezoe, Takayuki , Jamroziak, Krzysztof , Koh, Youngil, López, Maria Teresa Cibeira, Rios, Rafael, Garcia, Maria Esther Gonzalez, Chacón, Eusebio Martín, Valent, Jason Neil , Rosenzweig, Michael, Comenzo, Raymond L. , Gaballa, Mahmoud , Kaufman, Gregory P., Medvedova, Eva , Passero, Frank Charles , Stockerl-Goldstein, Keith , Chaulagain, Chakra P.

Mayo Clinic

Journal of Clinical Oncology | May 29, 2026 | Volume: 44 | Issue: 20 | Pages: 1899-1910

10.1200/jco-26-00755 | PMID 42212672 Get It

PURPOSE In immunoglobulin light chain (AL) amyloidosis, amyloid fibrils cause organ dysfunction. Anselamimab, a monoclonal antibody, selectively binds to amyloid fibrils, accelerating their clearance. METHODS Newly diagnosed patients with European modification of Mayo 2004 stage IIIa or IIIb AL amyloidosis were randomly assigned to receive anselamimab or placebo with cyclophosphamide, bortezomib, and dexamethasone (with or without daratumumab). The primary end point was a hierarchical composite of time to all-cause mortality (ACM) and frequency of cardiovascular hospitalizations (CVHs), analyzed using the Finkelstein-Schoenfeld test and win ratio estimation. RESULTS Among 406 randomly assigned patients, the primary end point win ratio for anselamimab versus placebo was 1.11 (95% CI, 0.83, 1.50; P = .332) and the hazard ratio (HR) for ACM was 0.80 (95% CI, 0.57, 1.13; P = .290). CVH rates in the anselamimab and placebo groups were 0.59 (95% CI, 0.42, 0.83) and 0.89 (95% CI, 0.55, 1.43), respectively ( P = .145). Among patients with kappa isotype (n = 72), the win ratio was 2.06 (95% CI, 0.98, 4.31; P = .100) and anselamimab reduced ACM by 62% versus placebo (HR, 0.38; 95% CI, 0.17 to 0.86; nominal P = .012), and CVH by 71% (IRR, 0.29; 95% CI, 0.10 to 0.87; nominal P = .028) with improvements in Kansas City Cardiomyopathy Questionnaire-Overall Score. There was no clinical benefit observed in the lambda population. Anselamimab was generally well-tolerated; safety data were comparable between treatment arms overall. CONCLUSION Treatment with anselamimab, an antifibril antibody used alongside antiplasma cell dyscrasia therapy, while not meeting the primary end point in the overall population, significantly improved ACM and CVH in patients with kappa AL, potentially offering a new therapeutic option for this isotype.
A23-20 Sleep Inequities Persist Over Time in Heavy Smokers
Baugh, A D, Barjaktarevic, I, Couper, D, Hansel, N N, Kaufman, J D, Ortega, V E, Woodruff, P G, Thakur, N, Zeidler, M R, Kaufman, Joel D. , Kaufman, Joel D , Baugh, Aaron , Hansel, Nadia N. , Zeidler, Michelle

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.1615 Get It

Abstract Rationale Sleep is an important dimension of COPD symptomology. Poor self-reported sleep quality has been independently associated with increased exacerbation risk and worse quality of life. There is limited evidence around the longitudinal sleep quality of patients with smoking-related lung disease. Methods Using the SPIROMICS longitudinal cohort of heavy smokers, we used group-based trajectory modeling to understand sleep quality over time as measured by serial retests of the Pittsburgh Sleep Quality Index (PSQI). We considered all participants of Black or Non-Hispanic White race who completed the PSQI in Visits 1-4, a span of 3 years. We considered race, gender, and social environmental exposures as time-stable risk factors for trajectory group membership. We adjusted for age, lung function, mood symptoms and self-reported COPD symptom severity were considered as time-varying factors. We selected the number of trajectory groups by minimizing Bayesian Information Criteria and polynomial order by maximizing the significance of exponential terms. For quality assurance we calculated average posterior probability of correct group assignment. Calculations were performed by complete case analysis and multiple imputation with chained equations. Results We analyzed 2,838 participants yielding 76,153 usable observations. Overall, 39.2% of participants had complete observations for all variables of interest at every measured visit, and 60.8% had at least one relevant observation missing. The largest single source of missingness in our dataset was the comorbidity count, for which 44% of participants had a missing observation. We identified two major trajectory groups. In one group, the PSQI was persistently high with little variation over time, containing 77.7% of the overall study population. The second group had low PSQI at baseline but experienced wide fluctuation over time. Risk factors for persistently poor sleep included female gender, Black race, and more adverse social conditions at either the neighborhood or individual level (Table). The average posterior probability of correct group assignment was 94.6% among the Low Variable group and 89.5% among the Persistent High group. Results were similar by complete case and imputed analysis, save that BMI did not independently predict group membership in the latter. Conclusion Historically underserved groups are at long term risk for poor sleep outcomes in smoking-related lung disease, even among those who are highly motivated and participate in clinical research. More work is needed to ensure equitable access to sleep medicine in order to improve the quality of care in COPD. This abstract is funded by: Nina Ireland Program for Lung Health
Human Spastic Muscle Remodels After Surgical Hyper-Selective Neurectomy
Wang, Zheng, Pichika, Rajeswari , Rhee, Peter, Kaufman, Kenton, Lieber, Richard, Rhee, Peter C , Kaufman, Kenton R. , Lieber, Richard L.

Mayo Clinic

Physiology | May 12, 2026 | Volume: 41 | Issue: S1 | Pages: No page available

10.1152/physiol.2026.41.s1.2289722 Get It

Background: Spasticity after upper motor neuron injury (stroke, spinal cord injury, etc.) alters muscle activity and induces long-term structural remodeling of skeletal muscle [1]. Elbow flexors, including the biceps brachii, are frequently affected, leading to abnormal tone, involuntary co-contraction, and impaired elbow function. Hyper-selective neurectomy (HSN) is a well-established surgical technique that has gained renewed clinical adoption with advances in anatomic understanding and intraoperative nerve mapping [2], yet its effects on muscle properties are poorly defined. Objective: The purpose of this study was to define pre- vs. post-HSN differences in muscle gene expression, sarcomere length, and clinical outcomes of the spastic human biceps. Methods: Individuals with elbow flexor spasticity undergoing a planned two-stage HSN were prospectively enrolled (n=10). Stage 1 released the elbow flexors and provided a pre-biopsy; Stage 2, performed ~3 months later to treat the forearm flexors, provided a second exposure to the biceps and a second biopsy. In both stages, biceps biopsies were obtained with customized clamps [3] at predefined elbow angles (50°, 90°, 135°), fixed, and analyzed for sarcomere length [4]. Total RNA was extracted from pre- and post-HSN biceps samples to characterize transcriptional changes. Clinical spasticity was assessed before Stage 1 and again before Stage 2 using the Modified Ashworth Scale (MAS). Data were compared using repeated-measures models, and single-cell transcriptional changes were analyzed using established analytical pipelines. Results: Sarcomere length (SL) increased significantly after HSN at all joint angles. At 50°, SL increased from 2.45 ± 0.18 µm pre-HSN to 3.05 ± 0.28 µm post-HSN; at 90°, from 2.70 ± 0.29 µm to 2.91 ± 0.16 µm; and at 135°, from 2.72 ± 0.36 µm to 3.24 ± 0.32 µm (all p < 0.05). Clinical spasticity assessment improved significantly as well (p < 0.05), with MAS scores decreasing from 1.89± 0.93 to 0.35 ± 0.53. RNA sequencing revealed changes in key pathways and overall gene expression patterns such as enhanced inflammatory response through increased cytokine production and fibroblast proliferation, leading to elevated collagen synthesis and subsequent fibrosis. We also observed upregulated immune modulation and chemotaxis, while pathways involved in mitochondrial respiration, muscle development, and cellular homeostasis were downregulated. At the transcript level, HSN led to decreased inflammation and adipogenesis, while promoting increased extracellular matrix assembly, and vascular formation. Conclusion: HSN produced coordinated improvements across structural, clinical, and transcriptional levels in the spastic human biceps muscle. Sarcomere lengths increased toward longer resting lengths at all joint angles, clinical spasticity decreased significantly, and RNA sequencing revealed distinct post-operative transcriptional remodeling. The longer sarcomere length and decreased spasticity should contribute to improved patient function after HSN. References: 1. Lieber RL et al. Muscle Nerve. 2002;26:98–105. 2. Leclercq C et al. Hand Clin. 2018;34:537–545. 3. Lieber RL et al. J Neurophysiol. 1994;71:874–881. 4. Ward SR et al. J Biomech. 2009;42:193–196. This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Percutaneous spinal stimulation to enhance gait and alleviate functional impairments in multiple sclerosis: A pilot study
Jahanian, Omid , Asp, Anders J., Gill, Megan L., Veith, Daniel D. , Fernandez, K. A. , Hogen, Cecilia A., Mills, Candee J. , Thoreson, Andrew R. , Grahn, Peter J. , Fernandez, Katrina A, Tobin, W Oliver , Fernandez, K A , Jahanian, Omid , Asp, Anders J., Solinsky, Ryan , Kaufman, Kenton R. , Zhao, Kristin D. , Tobin, W. Oliver

Mayo Clinic

Multiple Sclerosis Journal – Experimental, Translational and Clinical | April 29, 2026 | Volume: 12 | Issue: 2 | Pages: No page available

10.1177/20552173261432301 | PMID 42112095 Get It

Objective To evaluate the feasibility and potential efficacy of percutaneous spinal stimulation (epidural stimulation, ES) combined with task-specific training to reduce spasticity and improve gait and balance in individuals with progressive multiple sclerosis (MS). Methods Two men with progressive MS (EDSS 6.5) underwent ES lead implantation targeting the lower spinal cord, followed by one month of rehabilitation involving 12 ES-assisted training sessions. Assessments included instrumented gait analysis, Modified Ashworth Scale (MAS), pendulum test, and static balance testing performed at baseline, and at end of the study with ES-Off and ES-On conditions. Results Participant 1, with spastic hemiparetic gait, demonstrated improved lower extremity joint kinematics and muscle activation during gait, reduced knee extensor spasticity, and enhanced functional movement patterns with ES-On. Participant 2, with significant paraparesis and minimal spasticity, showed limited gait changes but experienced marked improvements in static balance, particularly under eyes-closed conditions. No adverse events were reported. Conclusion This pilot study demonstrates the feasibility and tolerability of ES paired with task-specific training in progressive MS. Participant-specific responses were observed, including improvements in gait kinematics, neuromuscular activation, spasticity, or balance; however, spatiotemporal gait parameters did not improve. These preliminary findings highlight response heterogeneity and the need for individualized ES parameter tuning. Trial registry name and URL: https://clinicaltrials.gov/study/NCT06019611
Clinical spectrum of hereditary hemorrhagic telangiectasia: data from the Comprehensive HHT Outcomes Registry of the US (CHORUS)
Al-Samkari, Hanny, Friday, Cassi , Kasthuri, R., Gossage, James R. , Murphy, Charles Griffin, Hountras, Peter, Kirkland, Kristi Jackson, Iyer, Vivek, Prasad, Vikas, Ahluwalia, Vaibhav, Rodriguez-Lopez, Josanna, Conrad, Miles , Hetts, S, Chakinala, Murali M. , Beasley, Melissa, Kirkpatrick, P., Lindquist, Jonathan , Battaile, John T., Lu, An, Parambil, Joseph G. , McCrae, KR, Sheynzon, V., Whitehead, Kevin, Sion, Cassidy, McWilliams, Justin P. , Cusumano, Lucas R. , Trerotola, Scott O. , Chesnutt, Mark S., Kaufman, Claire , Dickey, Melissa Ann, Krock, Nolie, Cottrill, Crystal, Competiello, Tania, Levy, Hara , Clancy, Marianne S. , Henderson, Katharine, Pollak, J., Iyer, Vivek , Al‐Samkari, Hanny , Kasthuri, Raj S. , Al-Samkari, Hanny , Kasthuri, Raj S , Murphy, Charles G , Iyer, Vivek N , Ahluwalia, Vaibhav , Rodriguez-Lopez, Josanna M , Conrad, Miles , Hetts, Steven , Ohliger, Michael , Sisk, Bryan A , Beasley, Melissa A , Lindquist, Jonathan , McCrae, Keith R , Whitehead, Kevin J , Cusumano, Lucas R , Drivas, Theodore G , Kaufman, Claire , Dickey, Melissa , Krock, Nolie , Smith, Karen L. , Kirkland, Kristi, Rodriguez‐Lopez, Josanna , Witkin, Alison S. , Hetts, Steven W. , Sisk, Bryan A. , Lu, An, Whitehead, Kevin J. , Drivas, Theodore G. , Dickey, Melissa , Boyce, Danielle M. , Pollak, Jeffrey

Mayo Clinic

Blood | March 17, 2026 | Volume: 148 | Issue: 4 | Pages: 417-432

10.1182/blood.2026033112 | PMID 41843464 Get It

Abstract Hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant vasculopathy affecting 1 in 5000 individuals, is the second most common inherited bleeding disorder worldwide. Despite this prevalence, comprehensive data on disease manifestations and complications remain limited. To address this gap, the US Congress allocated funding leading to the Comprehensive HHT Outcomes Registry of the United States (CHORUS), a prospective, 15-center longitudinal registry enrolling unselected patients with confirmed HHT. In this initial report, we describe findings from the first 600 participants, with a median age of 53 (range, 0-88) years and 60% female. Despite most participants developing typical HHT manifestations by age 13 years, the majority (63%) were not diagnosed until mid-to-late adulthood. Recurrent spontaneous epistaxis occurred in 95% of participants, chronic gastrointestinal bleeding in 30%, and heavy menstrual bleeding in 35% of postmenarche females, together resulting in moderate-to-severe mucosal bleeding in 76%. Iron deficiency and/or anemia were diagnosed in 68%, with 41% requiring IV iron and 25% requiring red cell transfusions. Serious complications of solid-organ arteriovenous malformations were frequent, including intracranial hemorrhage (3%), pulmonary hemorrhage (2%), venous thromboembolism (7%), arterial thromboembolism (11%), heart failure (7%), and pulmonary hypertension (7%). These data from CHORUS, the first national US registry of its kind, provide reliable, real-world estimates of the incidence, prevalence, and severity of numerous HHT manifestations and complications. HHT has a high burden of moderate-to-severe bleeding, anemia, thrombosis, and major neurologic and cardiopulmonary complications. There is a mean interval between first symptoms and diagnosis of &gt;2 decades, during which substantial, serious, and preventable HHT morbidity, including early intracranial hemorrhage, may occur. This trial was registered at clinicaltrials.gov as NCT06259292.